News
BCDAW
0.0200
-8.68%
-0.0019
BIOCARDIA COMPLETES ENROLLMENT OF CARDIAMP CELL THERAPY FOR THE TREATMENT OF CHRONIC MYOCARDIAL ISCHEMIA TRIAL OPEN LABEL ROLL-IN COHORT
Reuters · 19h ago
Weekly Report: what happened at BCDAW last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at BCDAW last week (0408-0412)?
Weekly Report · 04/15 09:34
Weekly Report: what happened at BCDAW last week (0401-0405)?
Weekly Report · 04/08 09:36
Weekly Report: what happened at BCDAW last week (0325-0329)?
Weekly Report · 04/01 09:36
Weekly Report: what happened at BCDAW last week (0318-0322)?
Weekly Report · 03/25 09:37
Weekly Report: what happened at BCDAW last week (0311-0315)?
Weekly Report · 03/18 09:36
Weekly Report: what happened at BCDAW last week (0304-0308)?
Weekly Report · 03/11 09:35
Weekly Report: what happened at BCDAW last week (0226-0301)?
Weekly Report · 03/04 09:36
Weekly Report: what happened at BCDAW last week (0219-0223)?
Weekly Report · 02/26 09:39
Weekly Report: what happened at BCDAW last week (0212-0216)?
Weekly Report · 02/19 09:40
Weekly Report: what happened at BCDAW last week (0205-0209)?
Weekly Report · 02/12 09:36
Weekly Report: what happened at BCDAW last week (0129-0202)?
Weekly Report · 02/05 09:39
Biocardia: Current report
Press release · 01/31 12:26
Weekly Report: what happened at BCDAW last week (0122-0126)?
Weekly Report · 01/29 09:36
Biocardia: Statement of changes in beneficial ownership of securities
Press release · 01/23 04:08
Weekly Report: what happened at BCDAW last week (0115-0119)?
Weekly Report · 01/22 09:37
Weekly Report: what happened at BCDAW last week (0108-0112)?
Weekly Report · 01/15 09:36
Biocardia: [Cover]SEC-generated letter
Press release · 01/08 22:40
Biocardia: Correspondence
Press release · 01/08 22:40
More
Webull provides a variety of real-time BCDAW stock news. You can receive the latest news about Biocardia through multiple platforms. This information may help you make smarter investment decisions.
About BCDAW
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.